Condition: Hyperactive Delirium · Delirium of Mixed Origin · Sponsor: Bruyère Health Research Institute.
The goal of this multi-centre phase I/II open-label, single-arm study is to determine the feasibility, optimal dose, and preliminary efficacy of dexmedetomidine to manage agitated delirium among patients near the end of life followed by a palliative care provider in a non-monitored setting. Fifty patients will receive dexmedetomidine (0.4 mcg/kg/hour, titrated up to 1.0 mcg/kg/hour) subcutaneously. Feasibility (recruitment rate, cost), safety (rate of adverse events), dosing, and preliminary efficacy (agitation, delirium severity) will be measured.
This description comes directly from the study's public registry record.
James Downar, MDCM, MSc · 6135626262 · jdownar@toh.ca
Julie Lapenskie, MSc · 6135626262 · jlapenskie@bruyere.org
Always discuss trial participation with your own doctor first.
| Foothills Medical Centre | Calgary, Alberta, Canada | Recruiting |
| The Ottawa Hospital | Ottawa, Ontario, Canada | Recruiting |
| Bruyère Continuing Care | Ottawa, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04824144